Quality of life among Children on Dialysis and Omega 3 Fatty Acid Supplementatio

Phase 3

• Conditions: Nutritional, Metabolic, Endocrine; Paediatrics; Kidney Disease

• Registration Number: PACTR202001481782473
• Lead Sponsor: Mohamed Samir

Brief Summary

Children with End Stage Renal Disease (ESRD) are liable to have poor quality of life. This work aimed to assess quality of life and study the effect of omega-3 fatty acid (?-3 FA) supplementation among children on dialysis. A pilot study was conducted on 31 hemodialysis children and an equal number of matched controls. Nonpharmacological treatments include dietary supplementation with ?-3 FA had been given to the patients for 16 weeks. PedsQL Measurement Model to measure quality of life (QOL) and laboratory investigations to assess the condition had been carried out. Patients had poorer QOL in comparison with controls especially regarding health activities (P<0.001). Poor QOL was reported among females and ages <12y (P<0.05). After ?-3 FA supplementation, the scores get improved not to the degree of controls scores but it showed some improvement (P<0.05). Lipid profile, inflammatory markers and efficiency of dialysis showed improvement (P<0.05). QOL among children on dialysis is affected by the disease. Beneficial effects of ?-3 FA were detected in children on dialysis reflected on improved quality of life. Further application on large sample to allow routine use for those patients is needed.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-18
• Results First Posted: 2020-01-18
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

Children with ESRD with
- A glomerular filtration rate of less than 10 ml/min/1.73 m2
- Age less than 14 years, and
- Regular hemodialysis at least three sessions per week for at least 3 months before the study will be included in the study.

Exclusion Criteria

Patients with
- Pre-dialysis stages of CKD,
- On chronic peritoneal dialysis,
- Regular hemodialysis < 3 months,
- Primary (non-uremic) cardiovascular disease will be excluded from the study.
Forty nine patients were enrolled, 31 patients (17 males and 14 females, aged from 8-14 years) fit the inclusion criteria while 18 patients were excluded (due to exclusion criteria, acute infection, hospitalization, febrile illness and non-compliance).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Study the effect of ?-3 FA administration on quality of life domains among studied patient group

Secondary Outcome Measures

Name	Time	Method
Inflammatory Markers